<DOC>
	<DOC>NCT00697151</DOC>
	<brief_summary>The study sought to assess the rate of recurrent stroke and death in stroke patients with a patent foramen ovale randomized to treatment with warfarin or aspirin. This was a multicenter study conducted at 48 U.S. Institutions.</brief_summary>
	<brief_title>Patent Foramen Ovale in Cryptogenic Stroke Study</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Foramen Ovale, Patent</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Age 3085 Ischemic stroke within 30 days Glasgow outcome scale â‰¥ 3 No contraindications to warfarin/aspirin Basal INR &gt; 1.4 Postprocedural stroke Severe carotid atherosclerosis Cardioembolic stroke Contraindications to transesophageal echocardiography</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>cerebrovascular diseases</keyword>
	<keyword>ischemic stroke</keyword>
	<keyword>patent foramen ovale</keyword>
	<keyword>warfarin</keyword>
	<keyword>aspirin</keyword>
	<keyword>transesophageal echocardiography</keyword>
</DOC>